orally administered Covid-19 vaccine candidate. According to Nadav Kidron, chief executive officer of Oramed, a comparable experiment is also being planned in Israel, as well as a Phase 2 trial in the United States.
newyorklatestnews.com
While there have been other clinical studies for the Covid-19 vaccine in South Africa, this would be the first for an oral therapy. If vaccines were delivered by mouth, Africa would overcome some of the challenges it has, such as the requirement to refrigerate the injectable injections, at times at extremely low temperatures, in order to boost vaccination rates on the continent that has the lowest vaccination rates. Kidron said, “South Africa is the first place in the world where we are running a clinical trial for this vaccine”.
Oravax, an Oramed subsidiary, developed a dosage that employs a virus-like particle to specifically target the three key surface proteins of Covid-19, including those that are less prone to mutation. According to the firm, this may be more effective against future coronavirus strains. While the vaccine may require refrigeration, he believes that the pills will be stable at room temperature based on the results of the studies. He said that authorisation for emergency usage in countries such as Mexico and Vietnam may be approved by the end of 2022.
According to Kidron’s statement, oral Covid vaccine is more beneficial than the injection. He said, “Oravax’s oral Covid-19 vaccine candidate could offer an exciting potential solution to the Covid pandemic, whether as a booster or for the unvaccinated. The oral form would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to administer the vaccine themselves at home”.
